Company / Cash & Equivalents
ATOSSA THERAPEUTICS, INC. Cash & Equivalents History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.5M
FY2016
5-year range
$0 / $8.5M
FY2012-FY2016
Trend
+0.0%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $6M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2016.
Improved from $6M to $9M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, cash & equivalents increased 0.0% year-over-year.
- Lowest cash & equivalents in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $8.5M | +0.0% |
| FY2015 | $8.5M | +34.0% |
| FY2014 | $6.3M | - |
| FY2013 | $0 | - |
| FY2012 | $0 | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026